RPG Life Sciences (BOM:532983) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532983 RPG Life Sciences Ltd BOM:532983
90 GF Score
Price ₹2,805.60
GF Value ₹2,575.61
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is RPG Life Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

RPG Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹ Mil. RPG Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹ Mil. RPG Life Sciences's annualized EBITDA for the quarter that ended in Jun. 2026 was ₹1,920 Mil. RPG Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for RPG Life Sciences's Debt-to-EBITDA or its related term are showing as below:

BOM:532983' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01   Med: 0.22   Max: 1.55
Current: 0.11

During the past 13 years, the highest Debt-to-EBITDA Ratio of RPG Life Sciences was 1.55. The lowest was 0.01. And the median was 0.22.

BOM:532983's Debt-to-EBITDA is ranked better than
84.93% of 677 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs BOM:532983: 0.11

RPG Life Sciences  (BOM:532983) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

RPG Life Sciences Debt-to-EBITDA Related Terms

RPG Life Sciences Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for RPG Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RPG Life Sciences Debt-to-EBITDA Chart

RPG Life Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

RPG Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BOM:532983 vs ZTS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RPG Life Sciences Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RPG Life Sciences's Debt-to-EBITDA falls into.


BOM:532983
90GF Score
RPG Life Sciences Ltd BOM:532983
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RPG Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

RPG Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(66.7 + 133.3) / 1768.8
=0.11

RPG Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / 1919.6
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is RPG Life Sciences (BOM:532983) Overvalued in 2026?

Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued. The current stock price of ₹2,805.60 is trading 8.9% above its estimated GF Value™ of ₹2,575.61. GuruFocus considers RPG Life Sciences to be Fairly Valued.

Key valuation signals for BOM:532983:

  • Debt-to-EBITDA:
  • GF Value™: ₹2,575.61 vs. price of ₹2,805.60 (8.9% above fair value)
  • GF Score™: 90/100 with 6 warning signs

No single metric tells the full story. See the BOM:532983 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RPG Life Sciences Business Description

Other Exchanges RPGLIFE:India
Address 463, Dr. Annie Besant Road, RPG House, Near Old Passport Office, Worli, Mumbai, MH, IND, 400030
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
90GF Score

Get the complete analysis for BOM:532983

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,805.60
Price
₹2,575.61
GF Value